Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Lexicon’s biopharmaceutical operations, financial condition, capital-raising activities and risks associated with its pipeline in heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes and related indications.
Investors can review current reports on Form 8-K, where Lexicon discloses material events such as quarterly financial results, at-the-market equity offering arrangements, Nasdaq listing status updates and key business developments. For example, recent 8-K filings describe an Open Market Sale Agreement with Jefferies LLC, legal opinions related to potential share sales, and communications regarding compliance with Nasdaq’s minimum bid price requirement and transfer to The Nasdaq Capital Market.
In addition to 8-Ks, users can locate Lexicon’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR), which typically contain audited financial statements, management’s discussion and analysis, detailed descriptions of products such as sotagliflozin (INPEFA®), pilavapadin (LX9211) and LX9851, as well as information on licensing agreements with partners like Viatris and Novo Nordisk. Proxy materials and other filings may address executive compensation, governance and shareholder matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy reports, helping users quickly understand major changes in revenue sources, R&D priorities, collaboration structures, risk factors and capital structure. Real-time updates from EDGAR ensure that new Lexicon filings, including any Form 4 insider transaction reports, become accessible promptly, while AI-generated overviews make complex regulatory language more approachable for both individual and institutional investors.
Lexicon Pharmaceuticals (LXRX) has resolved its Nasdaq listing deficiency. On 23 Jul 2025 the company received written notice from Nasdaq Listing Qualifications confirming that LXRX’s common stock has maintained a closing bid price at or above the $1.00 threshold long enough to regain full compliance with Rule 5550(a)(2). As a result, the prior non-compliance matter is formally closed and no further action is required by the company.
The 8-K contains no financial performance data, operational updates, or strategic announcements; its sole purpose is to inform investors that the risk of delisting has been removed. Regaining compliance preserves LXRX’s access to the Nasdaq Global Select Market, supporting share liquidity and investor confidence.
Lexicon Pharmaceuticals, Inc. (LXRX) disclosed in an 8-K filing that on July 3, 2025 it received written notice from Nasdaq Listing Qualifications granting the company an additional 180-day grace period—until December 30, 2025—to regain compliance with the $1.00 minimum bid-price requirement for continued listing. To secure the extension, Lexicon applied to transfer its shares from the Nasdaq Global Select Market to the Nasdaq Capital Market; Nasdaq has approved the transfer, which will become effective at the opening of trading on July 7, 2025.
During the second compliance period, the company must deliver a closing bid price of at least $1.00 for 10 consecutive business days. Eligibility for the extension remains contingent on meeting all initial Capital Market listing standards—except the bid price—and providing written confirmation that Lexicon intends to cure the deficiency, which may include effecting a reverse stock split if necessary.
The notice prevents an immediate delisting but underlines the ongoing risk that LXRX shares could be removed from Nasdaq if compliance is not restored by year-end. Investors should monitor management’s plans—particularly any potential reverse split—and the stock’s trading performance over the coming months.